Delving into the Latest Updates on Mometasone Furoate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ASCEND mometasone furoate-coated sinus balloon, Bioabsorbable mometasone-eluting sinus implants - Intersect ENT, Controlled-release-mometasone-furoate

+ [49]

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [5]

Active Indication

Chronic rhinosinusitis with nasal polypsRhinitis, Allergic, PerennialRhinitis, Allergic, Seasonal+ [18]

Inactive Indication

Acute sinusitisairway diseaseAsthma chronic+ [12]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Shionogi Pharma Co., Ltd.

Sandoz Pty Ltd.

Lyra Therapeutics, Inc.

+ [9]

Inactive Organization

Novartis Pharmaceuticals Corp.

Schering-Plough Research InstituteNovartis Pharma Services AG

+ [9]

License Organization

Beijing Xinglin Pharmaceutical Co. Ltd.LianBio

Beijing Jiu He Pharmaceutical Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (30 Apr 1987),

InflammationPruritus

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC27H30Cl2O6

InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N

CAS Registry83919-23-7

Atopic dermatitis (AD) is a chronic inflammatory skin condition with a high global prevalence and a multifactorial etiology. Its development is primarily attributed to defective skin barrier function, immune dysregulation, and oxidative stress-induced impairments in mitochondrial activity within keratinocytes. While mesenchymal stem cell-derived exosomes show promise as a cell-free therapy, their limited efficacy via traditional systemic administration is a major challenge. To address this, we developed a thermosensitive poloxamer hydrogel-based system for the local delivery of human umbilical cord mesenchymal stem cell-derived exosomes(hUCMSC-exo). Our in vitro studies demonstrated that hUCMSC-exo were effectively internalized by HaCaT keratinocytes, significantly mitigating inflammatory responses, abnormal differentiation, and mitochondrial damage caused by IL-4/TNF-α. Through RNA-seq and mechanistic validation, we found that hUCMSC-exo exert their protective effects by activating the Wnt/β-catenin signaling pathway, which repairs the skin barrier and reduces oxidative stress. We successfully prepared and characterized the hydrogel, confirming its excellent biocompatibility and sustained-release properties. In a MC903-induced AD mouse model, local administration of the hUCMSC-exo hydrogel significantly improved AD-like symptoms and lowered serum IgE and Th2 cytokine levels. Compared to the topical steroid mometasone furoate, our formulation demonstrated comparable efficacy with a superior safety profile. Our study is the first to combine a thermosensitive hydrogel with hUCMSC-exo for local delivery, providing a safe and effective new therapeutic strategy for AD.

01 Mar 2026·Explore-The Journal of Science and Healing

Efficacy and immunomodulatory effects of licorice nasal spray in allergic rhinitis: A clinical study comparing with conventional steroid treatment

Article

Author: Tsai, Ming-Shao ; Yang, Yao-Hsu ; Lin, Yu-Shih ; Chang, Geng-He ; Hsu, Cheng-Ming ; Tsai, Yao-Te ; Cheng, Yu-Ching ; Yang, Pei-Rung ; Wu, Ching-Yuan ; Chang, Pey-Jium

BACKGROUND:

Licorice (Glycyrrhiza glabra) is recognized for its anti-inflammatory and immune-regulating properties. It has demonstrated potential in managing inflammation associated with various respiratory and inflammatory disorders. This study aimed to evaluate the effectiveness and safety of a licorice nasal spray (LNS) compared to a conventional steroid nasal spray (SNS) in treating allergic rhinitis.

METHODS:

In a randomized clinical trial, 60 patients with allergic rhinitis were assigned to either LNS or SNS groups. The SNS group received mometasone furoate nasal spray (Nasonex®) administered as one spray per nostril twice daily (total daily dose 200 μg), while the LNS group received licorice nasal spray using the same dosing schedule. Both groups were treated twice daily for one month. Outcomes were assessed through symptom scores (TNSS, SNOT-22), Visual Analog Scale (VAS) for various symptoms, acoustic rhinometry, endoscopy, mucociliary transport time (MCTT), and cytokine levels in nasal secretions.

RESULTS:

Both LNS and SNS significantly reduced nasal blockage and postnasal drip. In addition, LNS was associated with improvements in rhinorrhea, itchy nose, and sleep quality. LNS was associated with significant reductions in IL-4, IL-6, IL-10, TNF-α, and IFN-γ in nasal secretions, whereas changes in SNS were observed in a more limited subset of cytokines. Additionally, LNS improved MCTT, indicating enhanced mucociliary function.

CONCLUSION:

Licorice nasal spray effectively reduces allergic rhinitis symptoms and demonstrates a meaningful immunomodulatory effect comparable to steroid nasal spray. These results indicate that LNS may be a promising alternative therapy for patients with allergic rhinitis.

TRIAL REGISTRATION:

This study is prospectively registered with ISRCTN under the identifier ISRCTN13188211. Registration was completed on 01/09/2022, ensuring transparency and adherence to clinical trial reporting standards. Full trial details are accessible at https://www.isrctn.com/ISRCTN13188211.

01 Feb 2026·ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY

Clinical Efficacy of Spray-Type Nasal Allergen Blocker as Adjuvant Treatment for Pediatric Allergic Rhinitis

Article

Author: Zhou, Mingyu ; Gao, Dongsheng ; Wang, Xin ; Ji, Wenjun ; Li, Jing ; Zhang, Tiantian

Objective::

To evaluate the clinical efficacy of Spray-Type Nasal Allergen Blocker as an adjuvant therapy for pediatric allergic rhinitis (AR).

Methods::

Eighty-two pediatric AR patients aged 4 to 14 years were included in this retrospective study and divided into 2 groups based on the treatments documented in their medical records: one treated with Mometasone Furoate Aqueous Nasal Spray (n = 38) and the other with a combination of a Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray (n = 44).

Results::

After 4 weeks of treatment, the total effective rate, the serum levels of IFN-γ, TGF-β, nasal ventilation area, ciliary movement rate, and pediatric Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores were higher in the Combination group than in Mometasone group, while the Total Nasal Symptom Score (TNSS) and nasal resistance were lower in the Combination group ( P < .05).

Conclusion::

Combination of Spray-Type Nasal Allergen Blocker and Mometasone Furoate Aqueous Nasal Spray exhibits promising results in the treatment of pediatric AR compared to Mometasone Furoate Aqueous Nasal Spray alone.

112

News (Medical) associated with Mometasone Furoate

12 Jan 2026

·firstwordpharma.com

Biopharma bites: Teva, Kinaset pull in funds, Camzyos wins in teens, plus contrasting fortunes for Lynk, Lyra

Teva again turns to Royalty for funding assistIn an effort to speed development of its anti-IL-15 antibody TEV-’408, Teva has sold certain rights to Royalty Pharma for up to $500 million, including an initial $75 million to support a Phase IIb study in vitiligo. Royalty Pharma also has an option to commit a further $425 million to co-fund a Phase III programme."This agreement…enables us to advance our science more efficiently and accelerate our pipeline," said Richard Francis, Teva's CEO. The Israeli drugmaker is increasingly investing in innovative medicines as part of its strategy to transition away from its pure-play generics past into a biopharmaceutical company.Teva said that emerging data from ongoing Phase Ib work provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions, with results set to be shared this year. TEV-'408 is also in Phase IIa development for coeliac disease.If TEV-'408 is approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of the drug. The agreement mirrors one signed between the parties in 2023 focused on a once-monthly subcutaneous version of Eli Lilly's atypical antipsychotic Zyprexa (olanzapine), known as TEV-'749, which was recently submitted to the FDA.Kinaset raises $103M to advance inhaled JAK inhibitorKinaset Therapeutics closed an oversubscribed $103-million series B round to advance frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor for patients with severe asthma inadequately controlled by standard maintenance therapies. The latest fundraise was led by RA Capital Management and Forge Life Science Partners, with contributions from new financers EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital and existing backers Atlas Venture, 5AM Ventures and Gimv.The biotech noted that the proceeds will fund a Phase II study of frevecitinib, which targets both eosinophilic and non-eosinophilic asthma phenotypes. "Frevecitinib has the potential to benefit all patients with severe asthma, including those with a non-eosinophilic phenotype," said Robert Clarke, chief executive of Kinaset.Kinaset debuted in 2020 backed by a $40-million series A commitment, alongside securing a global exclusive licence from Vectura to develop and commercialise frevecitinib.Lynk secures Phase III win for oral antirheumatic drugLynk Pharmaceuticals on Monday said its oral JAK1 inhibitor zemprocitinib (LNK01001) — commercially partnered with Simcere in Greater China — met the primary and key secondary goals in a Phase III trial involving patients with moderate-to-severe rheumatoid arthritis who have had an inadequate response to biologic disease-modifying drugs.The study enrolled 430 patients, who were randomised to receive zemprocitinib 12 mg or placebo twice daily, with the primary endpoint being ACR20 — a composite measure of disease improvement. At week 24, the ACR20 response rate with zemprocitinib was 79.1%, which was significantly greater than the 39.7% for placebo. Moreover, key secondary goals were also met, with the respective rates of ACR50 and DAS28 (CRP) ≤3.2 at week 24 for the zemprocitinib arm reaching 55.8% and 67.0%, respectively, compared with 22.0% and 23.4% for placebo.The company noted the experimental drug's safety profile was favourable, with most treatment-emergent adverse events being mild-to-moderate and no new safety signals were identified.Lyra suspends all drug development work Lyra Therapeutics will suspend further development of LYR-210 — a bioabsorbable implant designed to deliver six months of continuous mometasone furoate — for the treatment of chronic rhinosinusitis (CRS) in order to weigh strategic alternatives. The company cut 75% of its staff in mid-2024 following a Phase III failure for LYR-210.On Monday, Lyra said it will undertake another round of job reductions, which will impact its remaining 28 employees, as well as other cost-saving actions in order to buy more time. "The board has concluded that it is in the best interests of shareholders to cease Lyra's product development operations," remarked CEO Maria Palasis. The decision comes despite a second Phase III study of LYR-210 reading out positively this past June for the treatment of CRS without nasal polyps. Further, the company recently said that following a meeting with the FDA, it established a clinical development plan, which includes an additional late-stage trial to support the submission of a new drug application for LYR-210 in CRS without nasal polyps.As of September 30 last year, Lyra had approximately $22.1 million in cash, which is expected to last into the third quarter of 2026.BMS's Camzyos hits Phase III mark in teensBristol Myers Squibb reported positive topline results from a Phase III trial evaluating Camzyos (mavacamten) in 44 adolescents aged 12–17 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The SCOUT-HCM study met its primary endpoint, showing a statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 versus placebo, and achieved significance across multiple secondary endpoints as well. Safety findings were consistent with Camzyos' established adult profile, with no new safety signals.Camzyos, first approved by the FDA in 2022 for adults with symptomatic oHCM, has been prescribed to over 20,000 patients in the US alone. Monday's readout raises the possibility that Camzyos could become the first cardiac myosin inhibitor approved for adolescents, a population currently limited to medical symptom management or invasive surgery.BMS plans to present full results at an upcoming medical congress and engage with health authorities on potential regulatory submissions for adolescents.Last month, Cytokinetics' Myqorzo (aficamten) received FDA approval for adults with symptomatic oHCM.Matthew Dennis and Anna Bratulic contributed to this report.

Phase 3Phase 2Drug ApprovalClinical ResultLicense out/in

19 Dec 2025

·www.biospace.com

Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

iStock/ ALLVISIONN Insmed pointed to a strong placebo response as the reason for the trial’s failure. Insmed’s oral drug Brinsupri did not ease the burden of sinus symptoms in a mid-stage study of chronic rhinosinusitis without nasal polyps, forcing the New Jersey biotech to discontinue its program in this indication. Writing to investors on Thursday, analysts at Guggenheim Partners called the mid-stage miss a “rare disappointment” for Insmed—but one that nevertheless sent its shares tumbling 16% to $166.55 apiece at market close. “Based on our conversation with management, the BiRCh trial was well-conducted and delivered clear results, but the patients on placebo performed much better than expected,” Guggenheim noted. In the Phase IIb BiRCh study, Insmed enrolled nearly 290 patients who were randomly assigned to receive 10-mg Brinsupri, 40-mg Brinsupri or placebo, on top of their usual daily mometasone furoate nasal spray background therapy. Data presented on Thursday showed that at 24 weeks, patients given the respective doses of Brinsupri saw a 2.2- and 2.33-point decrease in the Sinus Total Symptom Score (sTSS), a tool used to measure rhinitis symptoms. While these changes indicated improvements due to treatment, there was also improvement in patients in the placebo arm, whose sTSS scores dropped 2.44 points at the same time point. In conversation with Guggenheim, Insmed management indicated that the BiRCh readout came earlier than expected. “Results were so unequivocal that they needed minimal time to process the results and decide to discontinue all further work in this indication,” the analysts said. Still, Guggenheim projects that the effects of Thursday’s rhinosinusitis fail will be “limited,” particularly given Brinsupri’s bright market prospects in non-cystic fibrosis bronchiectasis (NCFB). “We continue to see Brinsupri having ~$9Bn in peak sales potential in NCFB alone,” the analysts wrote. The BiRCh readout comes months after Insmed in June announced that its trepostinil palmitil inhalation powder (TPIP) aced a Phase IIb study in pulmonary arterial hypertension. Data presented at the time showed that TPIP led to a 35% improvement in pulmonary vascular resistance, a key measure of heart function, and to better six-minute walk distance. In its third quarter report , Insmed said that it would start a Phase III trial for TPIP in pulmonary arterial hypertension early next year. The biotech is also testing TPIP for pulmonary hypertension associated with interstitial lung disease, for which it expects to launch a late-stage study before the year ends. On Thursday, Guggenheim pointed to TPIP as one of the main reasons for its optimism about Insmed’s business. “We believe the Street continues to significantly underappreciate the potential for TPIP to become the preferred treprostinil across multiple large indications,” the analysts wrote.

Phase 2Clinical ResultPhase 3

18 Dec 2025

·www.fiercepharma.com

High-flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri

With the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps (CRSsNP), Insmed has discontinued its program to develop the newly approved, first-in-class DPPI inhibitor in the indication. Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication.With the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis without nasal polyps (CRSsNP), the New Jersey company has discontinued its program to develop the first-in-class DPPI inhibitor for the disorder, which would have brought a large patient population.The study did not meet any of its primary or secondary endpoints in either of the 10 mg or 40 mg treatment arms.As for the primary endpoint, Mizuho analyst Graig Suvannavejh, Ph.D., wrote in a note to investors that Brinsupri “failed spectacularly,” citing that patients had better outcomes with placebo than with either of the treatment doses.“Given that there are no animal models in this disease, the purpose of this proof-of-concept study was to determine if brensocatib could provide treatment benefit to patients with CRSsNP,” Martina Flammer, M.D., Chief Medical Officer of Insmed, said in a release. “While we are disappointed in the results, they provided us with a clear answer.”As a result, Mizuho sliced its peak annual sales projection for Brinsupri across all potential indications from $16 billion to $11 billion.After Insmed reported the failure late Wednesday, the company’s share price had fallen by 16% by mid-morning on Thursday.The lone positive from the trial is that Brinsupri was well-tolerated, with no new safety signals, including in the 40 mg arm, which is the highest dose the company has studied, exceeding its approved 10 mg and 25 mg dosages. In August, the FDA signed off on Brinsupri as a treatment for the rare respiratory disorder non-cystic fibrosis bronchiectasis (NCFB). In November, the European Union followed suit with a similar nod.In the same Dec. 18 release, Insmed announced the acquisition of Opsidio’s OpSCF, an investigational monoclonal antibody now known as INS1148. The company did not disclose financial details about the deal.Private Pennsylvania biotech Opsidio has been developing the antibody as a treatment for chronic inflammation. The program targets stem cell factor and was being developed in partnership with AbbVie.Opsidio was conducting a phase 2a trial of the asset in patients suffering from moderate-to-severe atopic dermatitis. Insmed is now picking up the program, which it believes has first-in-class potential for respiratory, immunological and inflammatory diseases with high unmet need, according to the release.Insmed said it plans on running phase 2 studies for INS1148 initially in interstitial lung disease and moderate-to-severe asthma. In the CRSsNP trial, which enrolled 288 participants across 104 sites, patients were randomized 1:1:1 for placebo, 10 mg Brinsupri and 40 mg Brinsupri. They received treatment for 24 weeks, which included the nasal spray background therapy mometasone furoate.As for the primary endpoint, the study used the patient-reported Total Nasal Symptom Score (TNSS), a 12-point measurement of a variety of nasal issues such as sneezing, runny nose, congestion and sleep disruption. While those on placebo reported a 2.44-point reduction from baseline, those in the 10 mg group reported a 2.21-point reduction and those in the 40 mg arm saw a 2.33-point reduction.Insmed is also investigating Brinsupri in the inflammatory skin disorder hidradenitis suppurativa (HS), with results from a phase 2 trial expected in the first half of next year. The company maintains an “optimistic view” in the indication because HS is a “strongly neutrophilic disease,” Muzuho reported, based on discussions with management on Wednesday night. Insmed has another lung disease drug on the market, Arikayce, which treats patients with mycobacterium avium complex (MAC). The amikacin liposome inhalation suspension treatment was approved in 2018 and generated sales of $364 million last year. In the first half of next year, Insmed expects to read out results from a trial of Arikayce as a first-line treatment for the disorder. The company also boasts a promising treatment for pulmonary arterial hypertension (PAH). In June, after reporting eye-opening phase 2 results for treprostinil palmitil inhalation powder (TPIP), Insmed saw a 27% spurt in its share price.

Phase 2Clinical ResultDrug ApprovalAcquisitionPhase 3

100 Deals associated with Mometasone Furoate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00690	Mometasone Furoate	R01AD09 R03BA07 D07XC03	DB14512

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Chronic rhinosinusitis with nasal polyps	United States	Intersect ENT, Inc.	08 Dec 2017
Asthma	United States	Organon & Co.	30 Mar 2005
Nasal Polyps	United States	Organon & Co.	15 Dec 2004
Pruritis (itchy skin)	Brazil	Libbs Farmacêutica Ltda.	28 Aug 2003
Rhinitis, Allergic	China	Schering-Plough Corp.	14 Jul 2000
Dermatitis	China	Merck & Co., Inc.	01 Jan 1999
Rhinitis, Allergic, Perennial	United States	Organon & Co.	01 Oct 1997
Rhinitis, Allergic, Seasonal	United States	Organon & Co.	01 Oct 1997
Alopecia Areata	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Drug Eruptions	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Eczema	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Erythema exudativum	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Erythrodermic psoriasis	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Impetigo	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Keloid	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Lupus Erythematosus, Discoid	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Pemphigoid, Bullous	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Pityriasis	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Prurigo	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993
Psoriasis	Japan	Shionogi Pharma Co., Ltd.	01 Oct 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic sinusitis	Phase 3	United States	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Austria	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Czechia	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Poland	Lyra Therapeutics, Inc.	27 Jan 2022
Chronic sinusitis	Phase 3	Spain	Lyra Therapeutics, Inc.	27 Jan 2022
Rhinitis perennial	Phase 3	China	Sichuan Otsuka Pharmaceutical Co. Ltd.	10 Apr 2019
Seasonal rhinitis	Phase 3	China	Sichuan Otsuka Pharmaceutical Co. Ltd.	10 Apr 2019
Sneezing	Phase 3	Argentina	PH & T SpA	01 Oct 2012
Congestion of nasal mucosa	Phase 3	-	Organon & Co.	01 Jul 2008
Intermittent asthma	Phase 3	Italy	Schering-Plough Corp.	15 Feb 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05295459 (CTgov)	Phase 3	Chronic sinusitis	182	Background therapy+LYR-210 (LYR-210)	hkfypnifjc(pwlakrqtls) = hzsbnmxwpf cpodjnlgpd (xzaocrnxqy, 0.239) View more	-	19 Feb 2026
				Background therapy (Sham Procedure Control)	hkfypnifjc(pwlakrqtls) = ivqtptfdde cpodjnlgpd (xzaocrnxqy, 0.332) View more
NCT05382494 (Pubmed \| JAMA Pediatr)	Phase 4	Sleep Apnea Syndromes	150	Intranasal mometasone furoate	sbivhuzqkn(yxwvyfofkz) = noakxhnzht ixggjxuvrh (rctokgmwww, 22.9 - 50.6)	Negative	20 Jan 2026
				Saline	sbivhuzqkn(yxwvyfofkz) = eimdltzemf ixggjxuvrh (rctokgmwww, 23.5 - 51.6)
NCT04849390 (ACESO, UEGW2024)	Phase 2	Eosinophilic Esophagitis	59	ESO-101 800 µg	uzvojcfrsn(aajevfqcwt) = acrtolbojt phomomnxmf (mxdaoozbkr, 88.42) View more	Positive	13 Oct 2024
				Placebo	uzvojcfrsn(aajevfqcwt) = nvrtbxieiw phomomnxmf (mxdaoozbkr, 65.11) View more
NCT03979209 (CTgov)	Phase 1	Chronic sinusitis	16	Nasal Mometasone Rinse (Mometasone 1mg)	awwlwidqlo(hwzquahsmk) = qawjcispee nsgemgwway (tfydhjttmv, jbbjjsngzv - vjyoeurkps) View more	-	12 Aug 2024
				Nasal Mometasone Rinse (Mometasone 2mg)	awwlwidqlo(hwzquahsmk) = nqgvzuicnf nsgemgwway (tfydhjttmv, lpwjzgyglj - sgfyggtmtn) View more
NCT04849390 ( ACESO , Biospace) Manual	Phase 2	Eosinophilic Esophagitis	43	ESO-101	rawlsccxrp(pcpknytbuw) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. tflmtqytwu (tvxxpewued )	Positive	05 Dec 2023
				placebo
NCT04041609 (CTgov)	Phase 2	Chronic sinusitis	71	LYR-210 (LYR-210 (Low Dose))	qstvynmucy(dxjtpxalnb) = rnqlpvpnwe ajayrinhjd (uhyvjhubwi, 0.637) View more	-	06 Jun 2023
				LYR-210 (LYR-210 (High Dose))	qstvynmucy(dxjtpxalnb) = glllsqjlbg ajayrinhjd (uhyvjhubwi, 0.651) View more
NCT03705793 (CTgov)	Phase 4	Rhinitis, Allergic \| Chronic sinusitis	53	Mometasone Furoate Nasal Irrigation (Mometasone Furoate Nasal Irrigation)	lijuobmxey(ydalhwsbau) = secrlpnwbs twtxmoirth (wudmeipinw, svhuuufjqy - qjajokiafe) View more	-	19 Dec 2020
				Mometasone Nasal Spray (Mometasone Nasal Spray)	lijuobmxey(ydalhwsbau) = eadvdlthdo twtxmoirth (wudmeipinw, rrawldbkhk - linibkwprd) View more
NCT01850823 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal	880	Mometasone Nasal Spray (NASONEX® Nasal Spray (Schering Corporation))	rwgmrgqcyl(bsofmzbptj) = duwhjjdlqv pkygsqhdjt (plwkwrghpa, 2.186) View more	-	19 Aug 2020
				Mometasone nasal spray (Mometasone Nasal Spray (Watson Laboratories, Inc))	rwgmrgqcyl(bsofmzbptj) = mnupcwzpcq pkygsqhdjt (plwkwrghpa, 2.223) View more
Pubmed \| Pulm Pharmacol Ther	Not Applicable	Asthma	739	Mometasone furoate 80 μg (Breezhaler®)	rxaicauafw(eqobmpibcw) = vbztsmjuum qwbccfdqpm (ahjvwwxpbu, -34 to 89)	-	01 Jun 2020
NCT02892344 (QUARTZ, Pubmed \| Respir Med) Manual	Phase 3	Asthma	802	indacaterol acetate+mometasone furoate	zyltggkgha(hbjfytzaqw): LSMD = 0.182, P-Value = <0.001 View more	Positive	01 Jan 2020
				mometasone furoate